BR112013020118A2 - derivado de macrolídeo substituído em posição c-4 - Google Patents

derivado de macrolídeo substituído em posição c-4

Info

Publication number
BR112013020118A2
BR112013020118A2 BR112013020118A BR112013020118A BR112013020118A2 BR 112013020118 A2 BR112013020118 A2 BR 112013020118A2 BR 112013020118 A BR112013020118 A BR 112013020118A BR 112013020118 A BR112013020118 A BR 112013020118A BR 112013020118 A2 BR112013020118 A2 BR 112013020118A2
Authority
BR
Brazil
Prior art keywords
macrolide derivative
substituted macrolide
substituted
derivative
macrolide
Prior art date
Application number
BR112013020118A
Other languages
English (en)
Inventor
Masato Hayashi
Kenichi Kanemoto
Masato Kashimura
Kou Kumura
Jun Kurosaka
Tomoaki Miura
Haruhisa Ogita
Naoki Sasamoto
Eiki Shitara
Tomohiro Sugimoto
Keiji Tamura
Yasunobu Ushiki
Kanako Yamamoto
Satoshi Yoshida
Original Assignee
Meiji Seika Pharma Co Ltd
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46721028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013020118(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meiji Seika Pharma Co Ltd, Taisho Pharmaceutical Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of BR112013020118A2 publication Critical patent/BR112013020118A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BR112013020118A 2011-02-21 2012-02-20 derivado de macrolídeo substituído em posição c-4 BR112013020118A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011034578 2011-02-21
PCT/JP2012/054677 WO2012115256A1 (en) 2011-02-21 2012-02-20 C-4" position substituted macrolide derivative

Publications (1)

Publication Number Publication Date
BR112013020118A2 true BR112013020118A2 (pt) 2017-07-18

Family

ID=46721028

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020118A BR112013020118A2 (pt) 2011-02-21 2012-02-20 derivado de macrolídeo substituído em posição c-4

Country Status (34)

Country Link
US (1) US9139609B2 (pt)
EP (1) EP2678349B1 (pt)
JP (1) JP5687777B2 (pt)
KR (1) KR20140008388A (pt)
CN (1) CN103492404B (pt)
AR (1) AR085286A1 (pt)
AU (1) AU2012222267B2 (pt)
BR (1) BR112013020118A2 (pt)
CA (1) CA2827474A1 (pt)
CL (1) CL2013002313A1 (pt)
CO (1) CO6801737A2 (pt)
CY (1) CY1117381T1 (pt)
DK (1) DK2678349T3 (pt)
ES (1) ES2566368T3 (pt)
HR (1) HRP20160252T1 (pt)
HU (1) HUE028245T2 (pt)
IL (1) IL227663A (pt)
IN (1) IN2013CN07459A (pt)
ME (1) ME02475B (pt)
MX (1) MX2013009585A (pt)
MY (1) MY161451A (pt)
NZ (1) NZ613956A (pt)
PE (1) PE20140649A1 (pt)
PL (1) PL2678349T3 (pt)
RS (1) RS54635B1 (pt)
RU (1) RU2599718C2 (pt)
SA (1) SA112330287B1 (pt)
SG (1) SG192655A1 (pt)
SI (1) SI2678349T1 (pt)
SM (1) SMT201600106B (pt)
TW (1) TWI513704B (pt)
UA (1) UA111191C2 (pt)
WO (1) WO2012115256A1 (pt)
ZA (1) ZA201305983B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5857008B2 (ja) * 2012-08-20 2016-02-10 大正製薬株式会社 C−4”位置換マクロライド誘導体を含有する医薬
CN105669798B (zh) * 2013-08-23 2019-07-26 普莱柯生物工程股份有限公司 一种大环内酯类化合物
CN103965273B (zh) * 2013-08-23 2016-05-25 普莱柯生物工程股份有限公司 一种大环内酯类化合物
CN103588833B (zh) * 2013-10-30 2016-08-17 北京科技大学 动物抗菌素泰拉霉素的制备方法
CN105085590A (zh) * 2014-05-16 2015-11-25 普莱柯生物工程股份有限公司 一种大环内酯类化合物
AR102810A1 (es) 2014-08-18 2017-03-29 Taisho Pharmaceutical Co Ltd Derivado de macrólido sustituido en la posición c-4
WO2017142002A1 (ja) * 2016-02-17 2017-08-24 大正製薬株式会社 C-4"位置換マクロライド化合物フリー体及び塩の結晶形並びにそれらの製造方法
CN108610388B (zh) * 2016-12-12 2020-11-06 浙江京新药业股份有限公司 一种大环内酯的制备方法
CN109425666B (zh) * 2017-08-28 2022-07-08 广东东阳光药业有限公司 一种酰氯衍生物的lc-ms分析方法
KR102672512B1 (ko) 2018-09-12 2024-06-10 노파르티스 아게 항바이러스 피리도피라진디온 화합물
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
CN111423482B (zh) * 2020-04-26 2023-01-17 梯尔希(南京)药物研发有限公司 一种同位素标记的红霉胺的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US5393743A (en) 1993-07-06 1995-02-28 Abbott Laboratories Erythromycin derivatives
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
RU2144541C1 (ru) * 1995-12-08 2000-01-20 Руссель Юклаф Производные эритромицина, способ их получения, промежуточный продукт, фармацевтическая композиция
EP1291352B1 (en) 1996-09-04 2005-05-25 Abbott Laboratories 6-O-substituted ketolides having antibacterial activity
UA51730C2 (uk) 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
US5804565A (en) 1996-09-24 1998-09-08 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
HN1998000074A (es) * 1997-06-11 1999-01-08 Pfizer Prod Inc Derivados de macrolidos c-4 sustituidos
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
US5972898A (en) * 1998-03-27 1999-10-26 Abbott Laboratories 3',3-N-bis-substituted macrolide LHRH antagonists
IL145739A0 (en) * 1999-05-24 2002-07-25 Pfizer Prod Inc 13-methyl-erythromycin derivatives
UY26964A1 (es) 2000-10-16 2002-06-20 Abbott Lab Derivados de eritromicina 6-0-sustituidos con mayor tolerancia gastrointestinal
US20080203485A1 (en) 2007-02-28 2008-08-28 International Business Machines Corporation Strained metal gate structure for cmos devices with improved channel mobility and methods of forming the same
WO2008106225A1 (en) * 2007-02-28 2008-09-04 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same

Also Published As

Publication number Publication date
US20140046043A1 (en) 2014-02-13
IL227663A (en) 2017-09-28
CN103492404A (zh) 2014-01-01
KR20140008388A (ko) 2014-01-21
CL2013002313A1 (es) 2014-08-08
DK2678349T3 (en) 2016-03-07
NZ613956A (en) 2014-07-25
CY1117381T1 (el) 2017-04-26
AU2012222267A1 (en) 2013-08-22
CA2827474A1 (en) 2012-08-30
SMT201600106B (it) 2016-04-29
ES2566368T3 (es) 2016-04-12
HRP20160252T1 (hr) 2016-04-22
HUE028245T2 (en) 2016-12-28
CN103492404B (zh) 2016-09-07
RU2013142898A (ru) 2015-03-27
PE20140649A1 (es) 2014-06-25
UA111191C2 (uk) 2016-04-11
IN2013CN07459A (pt) 2015-04-24
ME02475B (me) 2017-02-20
EP2678349B1 (en) 2016-01-13
EP2678349A4 (en) 2014-07-30
EP2678349A1 (en) 2014-01-01
IL227663A0 (en) 2013-09-30
SG192655A1 (en) 2013-09-30
SA112330287B1 (ar) 2015-10-11
TW201247693A (en) 2012-12-01
RU2599718C2 (ru) 2016-10-10
WO2012115256A1 (en) 2012-08-30
MX2013009585A (es) 2014-06-05
US9139609B2 (en) 2015-09-22
SI2678349T1 (sl) 2016-04-29
ZA201305983B (en) 2014-11-26
AR085286A1 (es) 2013-09-18
RS54635B1 (en) 2016-08-31
TWI513704B (zh) 2015-12-21
MY161451A (en) 2017-04-14
AU2012222267B2 (en) 2016-07-07
CO6801737A2 (es) 2013-11-29
JP2014505723A (ja) 2014-03-06
PL2678349T3 (pl) 2016-06-30
JP5687777B2 (ja) 2015-03-18

Similar Documents

Publication Publication Date Title
SMT201700065B (it) Derivato piridonico
BR112013014614A2 (pt) misturas de glicosídeo
BR112013020118A2 (pt) derivado de macrolídeo substituído em posição c-4
CO6910200A2 (es) Derivado de pirazoloquinolina
CO6970600A2 (es) Derivados de betulina
BR112013030180A2 (pt) peça de roupa de esporte
BR112014014736A2 (pt) braçadeira de porta
DK2590974T3 (da) Tetrahydropyridopyrimidinderivater
BR112014003440A2 (pt) unidade de dobramento
CO7020919A2 (es) Derivados de tetrahidro-quinazolinona
BR112014003441A2 (pt) unidade de dobramento
BR112013014392A2 (pt) compostos cetolídeos
BR112014011011A2 (pt) seções de estrutura de poços
CO6960557A2 (es) Derivados de 2-yodo-imidazol
DK2814329T3 (da) Ph-indstillet sødemiddel
FI20116167L (fi) Järjestely
CO6920301A2 (es) Derivados insecticidas de 2-metoxibenzamida
CO7020920A2 (es) Derivado de fenilazol sustituido
DE112013002564A5 (de) Nockenwelleneinheit
BRPI1007893A2 (pt) derivado de cianopirimidina
BR112013023316A2 (pt) derivados de difenila substituídos
CO6852074A2 (es) Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida
EP2671887A4 (en) NEW MACROLIDE DERIVATIVE
BR112013019806A2 (pt) derivado de tetrahidroisoquinolina.
ES2397885B1 (es) Derivados de colismicina.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2502 DE 18-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.